TY - JOUR
T1 - Antibody and T-Cell Responses against SARS-CoV-2 after Booster Vaccination in Patients on Dialysis
T2 - A Prospective Observational Study
AU - Kawashima, Moe
AU - Saito, Hiroaki
AU - Nishiuchi, Takamitsu
AU - Yoshimura, Hiroki
AU - Wakui, Masatoshi
AU - Tani, Yuta
AU - Nishikawa, Yoshitaka
AU - Omata, Fumiya
AU - Takita, Morihito
AU - Zhao, Tianchen
AU - Yamamoto, Chika
AU - Kobashi, Yurie
AU - Kawamura, Takeshi
AU - Sugiyama, Akira
AU - Nakayama, Aya
AU - Kaneko, Yudai
AU - Sawano, Toyoaki
AU - Shibuya, Kenji
AU - Kazama, Junichiro
AU - Shineha, Ryuzaburo
AU - Tsubokura, Masaharu
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/2
Y1 - 2023/2
N2 - Intensive vaccination is recommended for populations more vulnerable to COVID-19 infection, although data regarding the built of immunity after vaccination for dialysis patients are lacking. This prospective, observational cohort study of maintenance hemodialysis patients examined IgG antibody levels against the SARS-CoV-2 spike (S1) protein, neutralizing activity, and interferon gamma levels after the third dose of the BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) vaccine. Humoral immunity was repeatedly measured for up to two months. The study includes 58 patients on hemodialysis. Median neutralizing antibodies reached a maximum at 56 and 9 days after booster vaccination with BNT162b2 and mRNA-1273, respectively. The median IgG antibody titer reached a maximum of 3104.38 and 7209.13 AU/mL after 16 days of booster dose, and cellular immunity was positive in 61.9% and 100% of patients with BNT162b2 and mRNA-1273 vaccination, respectively. By repeating the measurements over a period of two months, we clarified the chronological aspects of the acquisition of humoral immunity in dialysis patients after a booster COVID-19 vaccination; most dialysis patients acquired not only humoral immunity, but also cellular immunity against SARS-CoV-2. Future research should investigate the continued long-term dynamics of antibody titers and cellular immunity after the third or further vaccinations, evaluating the need for additional vaccinations for hemodialysis patients.
AB - Intensive vaccination is recommended for populations more vulnerable to COVID-19 infection, although data regarding the built of immunity after vaccination for dialysis patients are lacking. This prospective, observational cohort study of maintenance hemodialysis patients examined IgG antibody levels against the SARS-CoV-2 spike (S1) protein, neutralizing activity, and interferon gamma levels after the third dose of the BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) vaccine. Humoral immunity was repeatedly measured for up to two months. The study includes 58 patients on hemodialysis. Median neutralizing antibodies reached a maximum at 56 and 9 days after booster vaccination with BNT162b2 and mRNA-1273, respectively. The median IgG antibody titer reached a maximum of 3104.38 and 7209.13 AU/mL after 16 days of booster dose, and cellular immunity was positive in 61.9% and 100% of patients with BNT162b2 and mRNA-1273 vaccination, respectively. By repeating the measurements over a period of two months, we clarified the chronological aspects of the acquisition of humoral immunity in dialysis patients after a booster COVID-19 vaccination; most dialysis patients acquired not only humoral immunity, but also cellular immunity against SARS-CoV-2. Future research should investigate the continued long-term dynamics of antibody titers and cellular immunity after the third or further vaccinations, evaluating the need for additional vaccinations for hemodialysis patients.
KW - cellular immunity
KW - COVID-19 vaccines
KW - humoral immunity
KW - renal dialysis
UR - https://www.scopus.com/pages/publications/85149204180
U2 - 10.3390/vaccines11020260
DO - 10.3390/vaccines11020260
M3 - 記事
AN - SCOPUS:85149204180
SN - 2076-393X
VL - 11
JO - Vaccines
JF - Vaccines
IS - 2
M1 - 260
ER -
